CFDA-SE is an effective tool for labeling and tracking the viability and distribution of cardiomyocytes in bioartificial myocardial tissue engineering.
Answers are grounded in this paper and cite their sources.
Enables viability tracking in bioartificial myocardial grafts; hypothesis-generating for tissue engineering, no clinical implications yet.
BACKGROUND: We demonstrate a method that includes colocalization studies to analyze cell suspensions after isolation and to characterize 3-dimensional grafts consisting of cells and matrix in vitro and in vivo. MATERIALS AND METHODS: Neonatal rat cardiomyocytes were labelled by CFDA-SE after harvest. Cells in the isolated cell suspension, the embodied cells in the seeded scaffolds were characterized measuring features such as viability and distribution of the cell types. RESULTS: Selective cell count revealed high yields of viable cardiomyocytes. After seeding cells in collagen matrix, viability of the cells decreased gradually in the time process in vitro. Histology of implanted bioartificial myocardial tissue detected viable cardiomyocytes within the graft. CONCLUSION: Using colocalization histology we could label and track cells within the bioartificial myocardial tissue graft in vitro and post implant and assess viability and distribution.
No takes yet. Share an insight, caveat, or question.
Mueller-Stahl et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: